Prognostic Value of Pretreatment Plasma Fibrinogen.

[pjoshea13]

New study below.

Fibrinogen circulates in the blood in readiness for clot formation. It requires the release of the enzyme thrombin for it to be converted into the fibrin strands that form a clot.

Fibrinogen above the normal range is associated with inflammation. It is one of the inflammatory markers associated with increased mortality in many settings. Inflammation is a treatable condition.

Nattokinase not only dissolves unwanted clots, but it also reduces fibrinogen levels.

In the new study:

"Elevated pretreatment plasma fibrinogen is associated with poorer survival in prostate cancer (OS {overall survival}: HR=2.26 ... CSS {cancer-specific survival}: HR=2.42" ...

-Patrick

ncbi.nlm.nih.gov/pubmed/307...

J Cancer. 2019 Jan 1;10(2):479-487. doi: 10.7150/jca.26989. eCollection 2019.

The Prognostic Value of Pretreatment Plasma Fibrinogen in Urological Cancers: A Systematic Review and Meta-analysis.

Song H1,2,3, Kuang G2,3, Zhang Z1,2,3, Ma B1,2,3, Jin J1,2,3, Zhang Q1,2,3.

Author information

1

Department of Urology, Peking University First Hospital, Beijing 100034, China.

2

Institute of Urology, Peking University, Beijing 100034, China.

3

National Research Center for Genitourinary Oncology, Beijing 100034, China.

Abstract

Objective: Growing evidence suggests pretreatment fibrinogen can serve as a prognostic marker in various malignancies. However, there are contradictory results about the prognostic role of fibrinogen in urological cancers. We conducted a meta-analysis to evaluate the association between pretreatment plasma fibrinogen and survival outcomes in urological cancers. Methods: After a systematic search of PubMed and Embase, we included 14 studies in our meta-analysis, and estimated hazard ratios (HRs) for overall survival (OS) and cancer-specific survival (CSS) using a fixed-effect model. Results: Our results indicate that pretreatment plasma fibrinogen is a prognostic factor in urological cancers (OS: HR=2.21, 95% CI=1.91-2.57, P<0.001, CSS: HR=2.67, 95% CI=2.23-3.19, P<0.001). Elevated pretreatment plasma fibrinogen is associated with poorer survival in prostate cancer (OS: HR=2.26, 95% CI=1.47-3.48, P<0.001; CSS: HR=2.42, 95% CI=1.44-4.07, P=0.001), renal cell carcinoma (OS: HR=2.13, 95% CI=1.75-2.61, P<0.001; CSS: HR=2.99, 95% CI=2.29-3.89, P<0.001) and upper tract urothelial carcinoma (OS: HR=2.34, 95% CI=1.81-3.02, P<0.001; CSS: HR=2.43, 95% CI=1.84-3.20, P<0.001). Subgroup analyses showed that plasma fibrinogen has a more negative impact on survival in Caucasian patients (OS: HR=2.52, 95% CI=1.95-3.25, P<0.001; CSS: HR=2.83, 95% CI=1.92-4.17, P<0.001) than Asian patients (OS: HR=2.07, 95% CI=1.73-2.49, P<0.001; CSS: HR=2.63, 95% CI=2.14-3.22, P<0.001). The prognostic value of fibrinogen is also consistent when stratified by different cut-off values. Conclusions: These results show that high pretreatment plasma fibrinogen levels can predict poorer OS and CSS in patients with urological cancers.

KEYWORDS:

biomarker; fibrinogen; meta-analysis; prognosis; urological cancers

PMID: 30719143 PMCID: PMC6360290 DOI: 10.7150/jca.26989

[snoraste]

I never had plasma fibrinogen lab work done. I do about two dozen items for my blood work. Perhaps that’s something you need to request? I’d also be curious if starting nattokinase AFTER would help

[pjoshea13 in reply to snoraste]

I believe so.

The prognostic value with some of these inflammation markers, is due to the fact that no-one does anything about them, IMO. Treating inflammation is like taking one's foot off the gas. It isn't in any way a cure for the cancer, but the cancer is no longer in such a hurry.

-Patrick

[snoraste in reply to pjoshea13]

Fair point. I have been taking nattokinase (NSK-SD formulation) per your previous comments for a few months now.

[Rilu]

Can we take nattokinase and vitamin k2-mk7 together? my husband is taking k2 together with D3 every morning, I do not know if we could add nattoquinase or both have conflicting effects ..

[pjoshea13 in reply to Rilu]

There is no conflict IMO.

I take my K2-mk7 after breakfast, & the nattokinase before bed, but not because I think there might be conflict.

-Patrick

[Rilu in reply to pjoshea13]

Thanks!!